专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1619203A1 GALECTIN 9-INDUCING FACTOR 审中-公开
标题翻译： GALECTIN 9-INDUZIERENDER FAKTOR
公开(公告)号：EP1619203A1
公开(公告)日：2006-01-25
申请号：EP04730110.6
申请日：2004-04-28
申请人： Galpharma Co., Ltd.
发明人： HIRASHIMA, Mitsuomi , NISHI, Nozomu , YAMAUCHI, Akira , YOSHIDA, Naoko , SEKI, Masako
IPC分类号： C07K14/52 , C12N15/09 , A61K38/22 , A61P5/38 , A61P29/00 , A61P35/00 , A61P37/06 , A61P37/08
CPC分类号： A61K38/1709 , C07K14/4726
摘要： It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to various physiological phenomena. Thus, a substance allowing the control of galectin 9 production and release is expected as exerting an activity of inducing antitumor and/or anti-inflammatory actions, etc. Therefore, it is required to reveal the same. It has been found that a factor inducing the production and release of galectin 9, "galectin 9-inducing factor", is contained in a certain solubilized tumor cell membrane fraction. This factor can be obtained as a concanavalin A-adsorbed fraction and as a concentrated active fraction by fractionation with an ion exchange column packed with Resource Q@, a hydroxyapatite column, etc. Assay reagents, drugs, assays, etc. can be developed by using the galectin 9-inducing activity of this factor.
摘要翻译：已经公开了作为凝集素的生理活性物质的半乳凝素9在各种细胞中表达，并且在半乳凝素9的表达水平与肿瘤的转移能力之间观察到相关性。因此，推测半乳凝素9与各种生理现象有关。因此，预期能够控制半乳凝素9的产生和释放的物质具有诱导抗肿瘤和/或抗炎作用的活性等。因此，需要显示相同的物质。已经发现，诱导半乳凝素9的产生和释放的因子“半乳凝素9诱导因子”被包含在某些溶解的肿瘤细胞膜级分中。可以通过用填充有Resource Q @，羟基磷灰石柱等的离子交换柱进行分级，作为伴刀豆素A吸附级分和作为浓缩的活性级分获得该因子。可以通过以下方法开发测定试剂，药物，测定等：使用该因子的半乳凝素9诱导活性。

2. 发明公开

EP1586325A1 DRUGS CONTAINING GALECTIN 9 审中-公开
标题翻译： GALECTIN 9 ENTHALTENDE ARZNEIMITTEL
公开(公告)号：EP1586325A1
公开(公告)日：2005-10-19
申请号：EP03815452.2
申请日：2003-08-21
申请人： Galpharma Co., Ltd.
发明人： HIRASHIMA, Mitsuomi Idai Shukusha B-404 , NISHI, Nozomu , YAMAUCHI, Akira , YOSHIDA, Naoko , SEKI, Masako
IPC分类号： A61K38/17 , A61K39/395 , A61K45/00 , A61K48/00 , A61P5/38 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00
CPC分类号： A61K38/1709 , C07K16/18
摘要： Galectin 9 exerts various functions depending on its localizations. On the other hand, galectin 9 is expected as participating in various biological functions. Thus, it has been required to clarify the detailed biological activities of galectin 9 and develop galectin 9-related techniques including development of drugs. Human galectin 9 shows a cytotoxic activity and an apoptosis-inducing activity on tumor cells but shows neither cytotoxic activity nor apoptosis-inducing activity on normal cells. Therefore, it is possible to employ galectin 9 proteins, galectin 9 agonists, galectin 9 antagonists, anti-galectin 9 binding protein antibodies, anti-galectin 9 binding sugar chain antibodies, galectin 9-producing, releasing or inducing substances, etc. as antitumor, antiallergic, immunosuppressive agents, drugs for autoimmune diseases, anti-inflammatory agents and active ingredients for adrenocortical steroid hormone alternatives.
摘要翻译： Galectin 9根据其定位具有各种功能。另一方面，半乳凝素9预期参与各种生物学功能。因此，需要阐明半乳凝素9的详细生物学活性，并开发包括药物开发在内的半乳凝素9相关技术。人半乳凝素9显示对肿瘤细胞的细胞毒活性和细胞凋亡诱导活性，但对正常细胞无细胞毒活性或细胞凋亡诱导活性。因此，可以使用半乳凝素9蛋白，半乳凝素9激动剂，半乳凝素9拮抗剂，抗半乳凝素9结合蛋白抗体，抗半乳凝素9结合糖链抗体，半乳凝素9产生，释放或诱导物质等作为抗肿瘤剂，抗过敏药，免疫抑制剂，自身免疫性疾病药物，抗炎剂和肾上腺皮质类激素替代物的活性成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式